204 related articles for article (PubMed ID: 30348809)
1. A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.
Spiciarich DR; Oh ST; Foley A; Hughes SB; Mauro MJ; Abdel-Wahab O; Press RD; Viner R; Thompson SL; Chen Q; Azadi P; Bertozzi CR; Maxson JE
Cancer Res; 2018 Dec; 78(24):6762-6770. PubMed ID: 30348809
[TBL] [Abstract][Full Text] [Related]
2. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
Maxson JE; Luty SB; MacManiman JD; Abel ML; Druker BJ; Tyner JW
J Biol Chem; 2014 Feb; 289(9):5820-7. PubMed ID: 24403076
[TBL] [Abstract][Full Text] [Related]
3. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
4. T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form.
Price A; Druhan LJ; Lance A; Clark G; Vestal CG; Zhang Q; Foureau D; Parsons J; Hamilton A; Steuerwald NM; Avalos BR
Biochem Biophys Res Commun; 2020 Feb; 523(1):208-213. PubMed ID: 31848046
[TBL] [Abstract][Full Text] [Related]
5. Mutational screens highlight glycosylation as a modulator of colony-stimulating factor 3 receptor (CSF3R) activity.
Hollander MJ; Malaker SA; Riley NM; Perez I; Abney NM; Gray MA; Maxson JE; Cochran JR; Bertozzi CR
J Biol Chem; 2023 Jun; 299(6):104755. PubMed ID: 37116708
[TBL] [Abstract][Full Text] [Related]
6. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
9. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.
Adam FC; Szybinski J; Halter JP; Cantoni N; Wenzel F; Leonards K; Brkic S; Passweg JR; Touw I; Maxson JE; Meyer SC
Curr Oncol; 2022 Feb; 29(2):805-815. PubMed ID: 35200567
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.
Zhang H; Coblentz C; Watanabe-Smith K; Means S; Means J; Maxson JE; Tyner JW
J Biol Chem; 2018 May; 293(19):7387-7396. PubMed ID: 29572350
[TBL] [Abstract][Full Text] [Related]
11. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
13. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
14. Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.
Zhang H; Means S; Schultz AR; Watanabe-Smith K; Medeiros BC; Bottomly D; Wilmot B; McWeeney SK; Kükenshöner T; Hantschel O; Tyner JW
Cancer Res; 2017 Aug; 77(16):4258-4267. PubMed ID: 28652245
[TBL] [Abstract][Full Text] [Related]
15. Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors.
Meenhuis A; Irandoust M; Wölfler A; Roovers O; Valkhof M; Touw IP
Biochem J; 2009 Feb; 417(3):737-46. PubMed ID: 18922133
[TBL] [Abstract][Full Text] [Related]
16. Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation.
Kesarwani M; Kincaid Z; Azhar M; Azam M
Blood Adv; 2024 Jun; 8(11):2765-2776. PubMed ID: 38531054
[TBL] [Abstract][Full Text] [Related]
17. Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation.
Druhan LJ; McMahon DP; Steuerwald N; Price AE; Lance A; Gerber JM; Avalos BR
Blood; 2016 Oct; 128(16):2097-2099. PubMed ID: 27581359
[No Abstract] [Full Text] [Related]
18. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
19. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.
Dwivedi P; Greis KD
Exp Hematol; 2017 Feb; 46():9-20. PubMed ID: 27789332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
